Johnson & Johnson announced that it has been selected as a Strategic Enterprise by the Hong Kong SAR Government's Office for Attracting Strategic Enterprises (OASES), marking a new chapter in the company's long-standing collaboration with Hong Kong. Johnson & Johnson sees strong alignment with Hong Kong's Five-Year Plan ambition to develop Hong Kong into a Health and Medical Innovation Hub with global influence. Building on more than five decades in the city, Johnson & Johnson will work alongside government, healthcare institutions, academia and ecosystem partners to advance health and medical innovation, strengthen clinical research and support the development of future healthcare talent.
Hong Kong's world-class healthcare institutions, strong clinical research environment, internationally connected scientific community and growing health and medical innovation ecosystem provide a unique platform for advancing healthcare innovation and delivering meaningful benefits for patients.
Strengthening Clinical Research and Scientific Exchange
Johnson & Johnson aims to build on Hong Kong's strengths in clinical excellence by supporting opportunities for clinical research and scientific collaboration. Through partnerships with healthcare institutions, researchers and the broader innovation ecosystem, the company hopes to help connect local expertise with regional and global innovation networks.
Supporting the Development of Future Healthcare Talent
Johnson & Johnson recognizes that talent is essential to the future of healthcare innovation. The company looks forward to exploring opportunities to support education, practical learning experiences, scientific exchange and knowledge sharing that help develop the next generation of healthcare and life sciences professionals.
Advancing Meaningful and Differentiated Innovation for Patients
Guided by its belief that health is everything, Johnson & Johnson will continue working with stakeholders across the healthcare ecosystem to explore opportunities that support timely patient access to meaningful innovation in areas of significant unmet need. The company remains committed to helping improve individual patient health outcomes and creating lasting value for patients, healthcare professionals and society.
Donatas Grabliauskas, General Manager, Johnson & Johnson Innovative Medicine Hong Kong & Macau, said:
"We are honored to become an OASES Strategic Enterprise and deepen our longstanding partnership with Hong Kong. This collaboration reflects a shared commitment to advancing health and medical innovation, strengthening research and developing the next generation of healthcare talent. By working alongside the HKSAR Government and partners across the healthcare ecosystem, we hope to harness the best of Hong Kong's strengths and Johnson & Johnson's global expertise to advance health innovation and make a meaningful difference in the lives of patients, families and communities across Hong Kong."